Surgery Combined with Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
A Prospective, Multicenter, Randomized Phase II Trial on Optimal Timing of Surgery Combined with Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Libing Xiang
- Phone Number: 2801 86 21 64041990
- Email: xiang.libing@zs-hospital.sh.cn
Study Contact Backup
- Name: Rong Jiang
- Phone Number: 2801 86 21 64041990
- Email: jiang.rong@zs-hospital.sh.cn
Study Locations
-
-
-
Foshan, China
- Recruiting
- The First People's Hospital of Foshan
-
Contact:
- Songhua Yuan
- Email: yuan-sh09@163.com
-
Guangzhou, China
- Recruiting
- Sun Yet-sen University Cancer Center
-
Contact:
- Chuyao Zhang
- Email: zhangchy@sysucc.org.cn
-
Hangzhou, China
- Recruiting
- Zhejiang Cancer Hospital
-
Contact:
- Yingli Zhang
- Email: zhangyl@zjcc.org.cn
-
Hangzhou, China
- Recruiting
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
Contact:
- Jianhua Qian
- Email: qianjianhua@zju.edu.cn
-
Hefei, China
- Recruiting
- The First Affiliated Hospital of University of Science and Technology of China
-
Contact:
- Ying Zhou
- Email: caddiezy@ustc.edu.cn
-
Shanghai, China
- Recruiting
- Zhongshan hospital, Fudan university
-
Contact:
- Libing Xiang
- Phone Number: 2801 862164041990
- Email: xiang.libing@zs-hospital.sh.cn
-
Contact:
- Libing Xiang
-
Shanghai, China
- Recruiting
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
-
Contact:
- Xipeng Wang
- Email: xipengwang@hotmail.com
-
Shanghai, China
- Recruiting
- Fudan University Cancer Hospital
-
Contact:
- Huijuan Yang
- Email: huijuanyang@hotmail.com
-
Shanghai, China
- Recruiting
- Obstetrics and Gynecology Hospital of Fundan University
-
Contact:
- Wei Jiang
- Email: jiangwei1436@fckyy.org.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Females aged ≥ 18 years.
- Pathologic confirmed stage IIIC and IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma
- Low, Middle tumor burden and high tumor burden with cPCI score ≤ 12 based on pre-operative CT or PET/CT examination
- Complete cytoreduction can be achieved based on CT or PET/CT examination
- Patients must agree to undergo BRCA (breast cancer gene) and HRD (homologous recombination deficiency) testing
- Performance status (ECOG 0-2)
Adequate bone marrow, renal and hepatic function to receive chemotherapy and subsequent surgery:
- white blood cells >3,000/µL, absolute neutrophil count ≥1,500/µL, platelets ≥100,000/µL, hemoglobin ≥9 g/dL,
- serum creatinine <1.25 x upper normal limit (UNL) or creatinine clearance ≥60 mL/min according to Cockroft-Gault formula or to local lab measurement,
- serum bilirubin <1.25 x UNL, AST(SGOT) and ALT(SGPT) <2.5 x UNL.
- Comply with the study protocol and follow-up.
- Patients who have given their written informed consent.
Exclusion Criteria:
- Non-epithelial ovarian malignancies and borderline tumors
- Low grade ovarian cancer
- Mucinous ovarian cancer
- Complete cytoreduction cannot be achieved according to preoperative evaluation, including pulmonary and hepatic parenchymal metastases, unresectable extensive pleural metastases, multiple thoracic lymph nodes metastases, brain or bone metastases
- Patient has a known hypersensitivity to the components of olaparib/bevacizumab or its excipients
- Synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ, thyroid carcinoma, or breast carcinoma (without any signs of relapse or activity, early-stage).
- Any other concurrent medical conditions contraindicating surgery or chemotherapy that could compromise adherence to the protocol.
- Other conditions, such as religious, psychological, and other factors, that could interfere with the provision of informed consent, compliance to study procedures, or follow-up.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Upfront cytoreductive surgery with maintenance therapy
Primary debulking surgery with a maximal cytoreduction of complete gross resection within 3 weeks after biopsy, followed by at least 6 cycles of adjuvant chemotherapy and maintenance therapy for patients with CR/PR after platinum-based therapy (patients with or without BRCA mutation will be maintained by PARPi or Bevacizumab respectively ).
|
Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
Other Names:
For patients with BRCA mutated, maintenance therapy of PARP inhibitors following CR/PR after first-line chemotherapy.
In this trial, Olaparib 300mg p.o. twice daily is suggested after the front-line therapy.
Other Names:
For patients without BRCA mutated, maintenance therapy of Bevacizumab following CR/PR after first-line chemotherapy.
In this trial, Bevacizumab 7.5mg per kilogram intravenous once every 3 weeks is suggested after the front-line therapy.
|
|
Active Comparator: Neoadjuvant chemotherapy with maintenance therapy
Neoadjuvant chemotherapy with 3 cycles of chemotherapy, then followed by interval debulking surgery.
The maximal time interval between course 3 chemotherapy and IDS is 6 weeks.
And then 3 cycles of adjuvant chemotherapy and maintenance therapy for patients with CR/PR after platinum-based therapy (patients with or without BRCA mutation will be maintained by PARPi or Bevacizumab respectively ).
|
3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
Other Names:
For patients with BRCA mutated, maintenance therapy of PARP inhibitors following CR/PR after first-line chemotherapy.
In this trial, Olaparib 300mg p.o. twice daily is suggested after the front-line therapy.
Other Names:
For patients without BRCA mutated, maintenance therapy of Bevacizumab following CR/PR after first-line chemotherapy.
In this trial, Bevacizumab 7.5mg per kilogram intravenous once every 3 weeks is suggested after the front-line therapy.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
3-year overall survival
Time Frame: Participants will be followed for at least 3 years after randomization
|
The proportion of patients alive at 3 years after entry into the study
|
Participants will be followed for at least 3 years after randomization
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival
Time Frame: Participants will be followed for at least 3 years after randomization
|
Time from entry into the study to any cause of death
|
Participants will be followed for at least 3 years after randomization
|
|
Progression-free survival
Time Frame: Participants will be followed for at least 3 years after randomization
|
Time from entry into the study to the diagnosis of the first progression or recurrence or death, whichever occurs first
|
Participants will be followed for at least 3 years after randomization
|
|
Post-operative complications
Time Frame: Participants will be followed up to 3 months after randomization
|
The surgical complications will be evaluated at 30-day, 60-day, 90-day after upfront cytoreductive surgery or interval debulking surgery
|
Participants will be followed up to 3 months after randomization
|
|
Quality of life assessments
Time Frame: Participants will be followed for at least 3 years after randomization
|
QLQ-C30, FACT-Q (baseline; 6 months, 12 months, 24 months and 36 months after randomization)
|
Participants will be followed for at least 3 years after randomization
|
|
Accumulated treatment-free survival
Time Frame: Participants will be followed for at least 3 years or death after randomization
|
Time from the date of randomization to death from any reason, minus the total treatment time of surgery and chemotherapy after randomization (regardless of targeted therapy)
|
Participants will be followed for at least 3 years or death after randomization
|
|
TFST
Time Frame: Participants will be followed for at least 3 years or death after randomization
|
Time from the date of randomization until the starting date of the first subsequent anticancer therapy or death, whichever occurred first, whichever occurred first
|
Participants will be followed for at least 3 years or death after randomization
|
|
TSST
Time Frame: Participants will be followed for at least 3 years or death after randomization
|
Time from the date of randomization until the starting date of the second subsequent anticancer therapy or death, whichever occurred first
|
Participants will be followed for at least 3 years or death after randomization
|
|
The pattern of the first relapse
Time Frame: Participants will be followed for at least 3 years or death after randomization
|
The number and sites of the first relapse, including pelvic, abdominal, retroperitoneal lymph nodes, distant metastases and ascites will be compared between the two groups.
|
Participants will be followed for at least 3 years or death after randomization
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Libing Xiang, Fudan University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Endocrine System Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Neoplasms by Histologic Type
- Genital Diseases, Female
- Endocrine Gland Neoplasms
- Neoplasms, Glandular and Epithelial
- Ovarian Diseases
- Adnexal Diseases
- Genital Neoplasms, Female
- Gonadal Disorders
- Carcinoma
- Fallopian Tube Diseases
- Carcinoma, Ovarian Epithelial
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Antineoplastic Agents, Immunological
- Antineoplastic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
- Poly(ADP-ribose) Polymerase Inhibitors
- Olaparib
Other Study ID Numbers
Other Study ID Numbers
- SAT-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.